Active, Not Recruiting
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT03946878
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive, +16 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States